Our research program ranks second nationally among all urology departments for National Institutes of Health funding, with amounts totaling more than $6.8 million. Our multi-dimensional, interactive and highly transformative approach to research provides the foundation for the department's strong research standing.
Conducting research to help advance men’s health in the fields of male reproductive medicine, sexual medicine and surgery.
Conducting research to improve the management and outcomes of patients born with congenital anomalies of the genitourinary system.
Evaluating techniques in robotic surgery and interventions to reduce kidney stone formation and recurrence.
Conducting research to eliminate the racial disparity in prostate cancer outcomes.
Studying care delivery and quality of care for urologic patients.
Developing new agents and interventions to improve outcomes and quality of life for patients with chronic pelvic pain and benign urologic conditions.
Developing the next generation of diagnostic and therapeutic nanoparticles.
Performing basic science and clinical research to improve the treatment and outcomes for children with urologic conditions.
Studying molecular, genetic and environmental contributors to prostate cancer to improve prostate cancer prevention, diagnosis and treatment.
Establishing new urologic tissue reconstruction models and developing treatment strategies for inflammation-based urologic conditions.
Conducting breakthrough research in genitourinary malignancies to develop novel therapeutics for bladder and kidney cancers.
Clinical trials test or study drugs, surgical procedures, medical devices or interventions with human subjects. Read more about our actively recruiting clinical trials.
Our department wants to support our investigators in their efforts by making sure they’re updated on all of our policies for conducting responsible research and the many resources available to them.
Dr. Desai is interested in the role of inflammation in prostate tumorigenesis. He is working under the mentorship of Dr. Kundu to study the potential link between inflammatory bowel disease and prostate cancer using both clinical samples as well as a murine model.
Dr. Ko is interested in quality and health outcomes particularly as it relates to urologic malignancies and will be working with Dr. Gregory Auffenberg to report on institutional outcomes relating to prostate cancer.
Dr. Vo is working with Dr. Greg Auffenberg on healthcare research and quality improvement. They are assessing postoperative opioid prescribing patterns in an effort to develop procedure-specific protocols to minimize overprescription.
Dr. Weiner is working with Dr. Edward Schaeffer to compare the molecular profiles of prostate cancer in men of African descent to those of men of European descent. This work may help understand and minimize racial disparities in prostate cancer survival.